Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)

Smith, M. R.Sandhu, S. K.George, D. J.Chi, K. N.Saad, F.Thiery-Vuillemin, A.Stahl, O.Olmos, D.Danila, D.Gafanov, R.Castro, E.Moon, H.Joshua, A. M.Mason, G. E.Espina, B. M.Liu, Y.Bevans, K. B.Lopez-Gitlitz, A.Francis, P.Fizazi, K.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/27059enHealth-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD)conference outputopen access10.1016/j.annonc.2021.08.10951569-8041http://www.annalsofoncology.org/article/S092375342103324X/pdf700527701046